LISATA THERAPEUTICS, INC. (LSTA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, Lisata Therapeutics, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual

Event · Shareholder vote
Also in this documentStock split

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 9, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LSTA
Neutral
high confidence
Mentioned
$LSTA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LSTANeutralLow
01

Why it matters

The new plans increase the authorized share pool, introducing dilution risk, while the reverse split proposal could alter share price dynamics.

02

Market read

The filing provides fresh corporate‑action data that may affect share supply and investor sentiment, but the immediate market impact is expected to be modest.

03

What to watch

Potential impact on employee retention and future fundraising capacity is not reflected in the immediate price move.

Relevance 6/10Novelty 6/10Timing: effective immediately after filing on Nov 9 2026

Background

Lisata Therapeutics filed an 8‑K detailing shareholder approvals of equity incentive plans, an ESPP, board elections, and a reverse split range.

Company-level read

Ticker impact

$LSTANeutralHigh confidence
Context

SEC Form 8‑K reports approval of a new 2026 Equity Incentive Plan and ESPP, plus board elections and a reverse split proposal, providing fresh corporate‑action details.

Expected impact

likely slight downward pressure as market prices in future dilution from the 2026 plans

Evidence & confidence

The filing discloses new share reserves (44.8M for the plan, 3.7M for ESPP) and a potential reverse split, both material to equity valuation.

Market effects

Minimal; primarily affects biotech‑sector micro‑cap investors tracking dilution risk.

U.S. market only; no broader regional effect.

Low; the filing is company‑specific without macro implications.

Counterpoint

The dilution may be offset by future financing needs, and the reverse split could boost price perception.

Key entities

  • Lisata Therapeutics, Inc.

    Biotech firm filing the 8‑K.

  • Cynthia L. Flowers

    Elected Class I director.

  • Dr. Ted W. Love, M.D.

    Elected Class I director.

Related articles

$LSTAMedAI 8/10

Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

$LSTAMedAI 8/10

Marea Therapeutics doses first patient in MAR002 phase 2 trial

Lisata Therapeutics' (LSTA) subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, a treatment for acromegaly. The trial aims to enroll 72 participants, with primary endpoint measuring IGF-1 reduction after 10 weeks. MAR002 could offer less frequent dosing than current treatments. Lisata's valuation may be impacted by clinical milestones, according to InvestingPro.

$LSTALow

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.